Jorie Versmissen
Overview
Explore the profile of Jorie Versmissen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
999
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Minnema J, Sablerolles R, Kempen J, van der Kuy H, Polinder-Bos H, de Loo B, et al.
BMC Infect Dis
. 2025 Mar;
25(1):337.
PMID: 40065242
No abstract available.
2.
Wilkes S, Kalfsvel L, van Rosse F, Versmissen J, van der Kuy H, Zaal R
Eur J Hosp Pharm
. 2025 Feb;
PMID: 39929710
Objectives: Specialised hospital pharmacists, integrated in medical teams on the ward, can improve medication safety. When a specialised hospital pharmacist is temporarily not available, the pharmaceutical care will be conducted...
3.
Minnema J, Sablerolles R, Kempen J, van der Kuy H, Polinder-Bos H, de Loo B, et al.
BMC Infect Dis
. 2025 Feb;
25(1):165.
PMID: 39905298
Objectives: The scarcity of intensive care unit (ICU) beds during the COVID-19 pandemic has led to a large number of national and international guidelines for the triage of ICU admission....
4.
Versmissen J, van Steenkiste J, Koch B, Peeters L
Br J Clin Pharmacol
. 2024 Jun;
90(8):1884-1891.
PMID: 38845455
Antihypertensive drugs do not qualify as optimal candidates for therapeutic drug monitoring (TDM), given their obvious physiological effect, the absence of a clear relationship between drug concentrations and pharmacodynamic outcomes...
5.
Zeijen V, Peeters L, Asman A, Boersma E, Massey E, van Dijk L, et al.
J Hypertens
. 2024 May;
42(10):1687-1694.
PMID: 38780122
Objective: To assess the impact of personalized feedback on therapy adherence testing results on quality of life and beliefs about medication in patients with resistant hypertension, as well as to...
6.
Buijs S, van Dorst D, Kruip M, van den Akker R, Cheung K, Porrazzo R, et al.
Biomed Pharmacother
. 2023 Dec;
170:115969.
PMID: 38042112
Background: Tamoxifen is an effective treatment for primary breast cancer but increases the risk for venous thromboembolism. Tamoxifen decreases anticoagulant proteins, including antithrombin (AT), protein C (PC) and tissue factor...
7.
van Dorst D, Mirabito Colafella K, Van Veghel R, Garrelds I, de Vries R, Mathijssen R, et al.
Eur J Pharmacol
. 2023 Nov;
962:176199.
PMID: 38029870
Background: Anticancer angiogenesis inhibitors cause hypertension and renal injury. Previously we observed in rats that high-dose aspirin (capable of blocking cyclooxygenase (COX)-1 and-2) was superior to low-dose aspirin (blocking COX-1...
8.
Peeters L, Kappers M, Hesselink D, van der Net J, Hartong S, van de Laar R, et al.
J Hypertens
. 2023 Oct;
42(1):169-178.
PMID: 37796233
Background: Adherence to antihypertensive drugs (AHDs) is crucial for controlling blood pressure (BP). We aimed to determine the effectiveness of measuring AHD concentrations using a dried blood spot (DBS) sampling...
9.
van Hylckama Vlieg M, Nasserinejad K, Visser C, Bramer W, Ashrani A, Bosson J, et al.
EClinicalMedicine
. 2023 Sep;
64:102194.
PMID: 37731937
Background: The optimal duration of anticoagulation in patients with active cancer and venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate anticoagulant therapy for 3-6 months and to continue anticoagulant...
10.
Kalfsvel L, Wilkes S, van der Kuy H, van den Broek W, Zaal R, van Rosse F, et al.
Eur J Hosp Pharm
. 2023 Aug;
PMID: 37652663
Objectives: Prescribing errors can lead to inconvenience, morbidity and mortality. It is therefore crucial to educate doctors to prescribe safely, efficiently and effectively. To create an effective educational programme, it...